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Introduction: Systemic sclerosis (SSc) is an autoimmune disorder, which frequently affects the
lungs, with manifestations of interstitial lung disease (ILD) with lung fibrosis and of pulmonary
hypertension. The pathogenesis remains largely unrecognised.
Objective: The aim of this study was to elucidate the inflammation in the bronchial mucosa in
patients with SSc.
Subjects and methods: Twenty-three subjects diagnosed with SSc participated. Twelve of the
SSc patients showed signs of ILD, four were smokers and seven were treated with oral cortico-
steroids. Seventeen non-smoking, age- and sex-matched healthy subjects served as controls.
Bronchoscopy was performed to sample endobronchial mucosal biopsies, which were immuno-
histochemically stained using a panel of antibodies against inflammatory markers.
Results: The number of neutrophils was significantly elevated in the submucosa of SSc
patients, regardless of ILD, or whether the subject was smoking or using oral corticosteroids.
No up-regulation of neutrophil chemoattractants or cytokines was seen in the bronchial epithe-
lium. The signal transduction pathways and adhesion molecule expression tended to be sup-
pressed or unchanged in SSc patients compared with controls.
Conclusion: It is concluded that SSc is associated with a chronic neutrophilic inflammation in
the bronchial mucosal, with signs of suppressed signal transduction, regardless of the presence
of interstitial lung disease.
ª 2008 Elsevier Ltd. All rights reserved.785 6892; fax: þ46 90 130 953.
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302 M. Sehlstedt et al.Introduction ILD and five with ILD). Four of the patients, all without oralTable 1 Clinical characteristics of 23 patients with
systemic sclerosis.
Variable SSc without
ILD on HRCT
(NZ 11)
SSc with
ILD on HRCT
(NZ 12)
P-value
Median
(25the75th
percentile)
Median
(25the75th
percentile)
Age, years 53 (16) 64 (10) 0.02
Sex females/males 10/1 8/4
Disease duration,
years
14 (21) 6 (6) 0.04
Limited/Diffuse
cutaneous SSc
10/1 3/9
Skin score 1.0 (2.0) 2.0 (3.0)
Previous scleroderma
renal crisis
0 1
Oesophagus involvement6/11 6/12
Anticentromere-/
anti-scleroderma 70/
Anti-ribonucleoprotein
antibodies
8/1/1 3/5/2
Sjo¨gren’s syndrome 1 5
Smokers 2 2
Oral corticosteroid
treated
2 5
VC % of predicted 116 (104e122)99 (87e113) 0.09
TLC % of predicted 112 (103e120)91 (88e111) 0.02
FEV1 % of predicted 97 (89e104) 96 (83e110) 0.81
DLCO % of predicted 100 (93e102) 97 (91e106) 0.81
VCZ vital capacity; TLCZ total lung capacity; FEV1Z forced
expired volume during the first second; DLCOZ diffusion cap
acity for carbon monoxide.Systemic sclerosis (SSc) is an autoimmune disorder char-
acterised by inflammation, vascular involvement and
excessive fibrosis of the skin and also involvement of
internal organs, such as the lungs, kidneys, heart and
gastrointestinal tract.1,2 Despite the fact that SSc has been
identified as a disease entity for a long period of time, the
pathogenesis remains largely unrecognised and there is no
curative treatment. The prognosis of SSc is dependent on
the degree of involvement of internal organs. Pulmonary
hypertension and interstitial lung disease (ILD) with lung
fibrosis are frequent lung manifestations in SSc. Pulmonary
hypertension includes thickening and scarring of the blood
vessel walls, resulting in narrow vessels.3 The development
of ILD often starts with infiltration of inflammatory cells
and interstitial oedema, together with fibroblast prolifer-
ation and collagen deposition, whereas the established lung
fibrosis include fibrosis of the alveolar septal interstitiae,
fusion of the alveolar walls, and loss of functional alveolar
capillary units. Increased collagen deposition leads to
a more rigid lung structure and an accompanied decline in
lung function. Both pulmonary hypertension and ILD with
fibrosis significantly reduce life expectancy.1,4
Analyses of bronchial alveolar lavage fluid (BAL) have
shown increased numbers of neutrophils, eosinophils and
mast cells as well as increased levels of matrix metal-
loproteinase-9 (MMP-9) and a number of cytokines.5e7 In
contrast, the inflammatory state of the bronchial mucosa,
in SSc, has to our knowledge not been previously explored.
We reasoned that the inflammatory state in the lower
airways, as reflected in BAL fluid,5 would be accompanied
by increased numbers of inflammatory cells in the bronchial
wall.
The primary hypothesis was that patients with SSc would
differ from healthy age-matched controls, in terms
neutrophil numbers, in the bronchial mucosa. The second
hypothesis was that SSc patients with ILD would reveal
a more pronounced bronchial inflammation than those
without ILD. Additionally, we set out to explore, more in
detail, the inflammatory state in the bronchial mucosa in
SSc and the importance of the bronchial epithelium in the
regulation of inflammatory responses.
Patients and methods
Subjects
Twenty-three patients (18 women and five men) with SSc,
according to the diagnostic criteria of American College of
Rheumatology (formerly the American Rheumatism Associa-
tion)8 were enrolled in the investigation. Twelve of the SSc
patients had interstitial lung disease (ILD) as determined by
high resolution computed tomography (HRCT), whereas 11 of
the SSc subjects did not. The majority of the ILD patients had
limited reticulate pattern fibrosis in the lower lobes, whereas
three patients showed extensive radiological fibrotic
changes. Six patients had secondary Sjo¨gren’s syndrome, of
whom five had ILD. None of the 23 patients were diagnosed
with rheumatoid arthritis. Seven patients, five women and
twomen,were treatedwith oral corticosteroids (twowithoutsteroid treatment, (two men with ILD and two women
without ILD) were smokers. The clinical characteristics of the
patients are summarised in Table 1. Patientswith SScwith ILD
were confirmed to have restrictive lung function impairment
as demonstrated by significantly reduced total lung capacity
(PZ 0.02). Diffusion capacity was less sensitive in displaying
lung function impairment in the ILD group (Table 1). Patients
with diffuse SSc had significantly more often ILD.
Seventeen (14 women and three men) non-smoking, age-
and sex-matched healthy subjects with normal lung func-
tion randomly selected from the Swedish population
registry served as controls. None of the subjects had
experienced any signs of airway infection within 6 weeks
prior to the bronchoscopy investigation. The study was
approved by the Ethics Committee of the University
Hospital in Umea˚ and all subjects gave their written
informed consent.
High resolution computed tomography (HRCT)
of the lungs
To confirm ILD, a HRCT of the lungs were performed in the
SSc patients with a Philips Tomoscan LX Single slice scanner
(MA, USA). Scans were performed at full inspiration in the
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uous scans throughout the lungs with 10 mm thickness fol-
lowed by scans with 1.5 mm thickness with a slice spacing
of 30 mm.5
Bronchoscopy
Fiberoptic bronchoscopy was performed to obtain endo-
bronchial mucosal biopsies, using a flexible video bron-
choscope, Olympus BF T10 or T20 (Olympus, Tokyo, Japan).
The bronchoscope was inserted via the mouth with the
subject in a supine position. The endobronchial mucosal
biopsy specimens were sampled either from the anterior
aspect of the main carina and the subcarinae of the 3rd and
4th generation airways of the right side, or from the
posterior aspect of the main carina and the corresponding
subcarinae on the left side.9
Fixation and immunohistochemical staining of lung
biopsy samples
The staining and quantification procedures have previously
been described in detail.9e11 Briefly, endobronchial mucosal
biopsy specimens were fixed overnight in a solution con-
taining chilled acetone and protease inhibitors before being
processed into glycol methacrylate (GMA) resins.9 The fixed
biopsies were cut in two micron thin sections and placed on
glass slides. Endogenous peroxidaseswere inhibited and non-
specific antibody binding was blocked before the primary
antibodies were applied and incubated over night. The
monoclonal antibodies used were directed against early
signal transduction pathways (JNK, p38, ERK, c-Jun, c-Fos,
p65), proinflammatory mediators (interleukin (IL)-8, Gro-a,
ENA-78), pan-endothelial marker (EN4), vascular endothelialTable 2 Antibodies used for immunohistochemical staining of
activated protein kinases and transcription factors.
Antibody against Marker Clone
IL-8 Interleukin 8 NAP II
Gro-a Gro-a 20326.1
ENA-78 ENA-78 33160.111
p-p38 p 38 D-8
p-JNK c-jun N-terminal kinase G-7
p-ERK Extracellular signal-regulated
protein kinase
E-4
p-C-Jun Activator protein-1 KM-1
p-C-Fos Activator protein-1 D-1
NFkB (p65) Nuclear factor-k-B 20
CD3 CD3 T lymphocytes UCHT 1
CD4 CD4 T helper cells MT310
CD8 CD8 Cytotoxic T cells C8/144B
NE Elastase, neutrophils NP57
AA1 Tryptase, mast cells AA1
CD62P P-selectin, microvasculature AK-6
CD54 ICAM-1, microvasculature 6.5B5
EN4 Endothelium, microvasculature EN4adhesion molecules (p-selectin, ICAM-1) and inflammatory
cells (neutrophils, mast cells, T cells) (see Table 2). Finally,
an enzyme-conjugated (biotinylated) secondary antibody
was added before the sections were visualised by adding an
enzyme specific substrate and counterstained with Mayer’s
haematoxylin as previously reported.9e13 Diaminobenzidine
(DAB) was used to yield a brown colour as a marker for posi-
tive staining of epithelial markers while 3-amino-9-ethyl-
carbazole (AEC)was used for the staining of cells andmarkers
in the vasculature.
Evaluation of the immunohistochemical staining
The immunoreactivity of the staining was evaluated using
a light microscope and computer-assisted image analysis
equipment. The image analysis equipment included
a colour video camera [Sony DXC-950P 3-CCD three chip
power HAD (power Hole Accumulated Diode, Charge-
Coupled Device)] with 380,000 effective pixels (Sony,
Tokyo, Japan) connected to a LEICA Imaging Workstation
with dedicated software (Leica Q500IW, Leica Cambridge,
UK). Images of the immunohistochemical staining and an
example of the image analysis technique are demonstrated
in Fig. 1.
Cells
The quantification of positively stained immune cells was
carried out using a light microscope. Cells were counted
separately in the epithelium and the submucosa, excluding
mucosal glands, blood vessels and smooth muscle. The
length of the epithelium and the area of the submucosa
were quantified using the computer-assisted image analy-
ser. In the epithelium, counts were expressed as cells/mm
and in the submucosa as cells/mm2.13inflammatory cells, cytokines, adhesion molecules, mitogen
Isotype Source
IgG1 Boehringer Ingelheim,
Heidelberg
Monoclonal mouse IgG2b R&D, Abingdon, UK
Mouse IgG1 R&D, Abingdon, UK
Mouse monoclonal IgM Santa Cruz, CA, USA
Mouse monoclonal IgG1 Santa Cruz, CA, USA
Mouse monoclonal IgG2a Santa Cruz, CA, USA
Mouse monoclonal IgG1 Santa Cruz, CA, USA
Mouse monoclonal IgG2b Santa Cruz, CA, USA
Mouse IgG1 Becton Dikinson Pharmingen,
CA, USA
IgG1 kappa Dako, Glostrup, Denmark
IgG1 kappa Dako, Glostrup, Denmark
IgG1 kappa Dako, Glostrup, Denmark
IgG1 kappa Dako, Glostrup, Denmark
IgG1 kappa Dako, Glostrup, Denmark
IgG1 Serotec Oxford UK
IgG1 kappa Dako, Glostrup, Denmark
IgG1 Monsan, Uden, the Netherlands
Figure 1 Immunostaining of bronchial epithelium and inflammatory cells in the submucosa with monoclonal antibodies. Arrows
indicate nuclear staining. A and B demonstrate staining of neutrophils (neutrophilelastase). A corresponds to a tissue section with
high amount of neutrophils and B with low. C and D both demonstrate NFkB (p65) staining in the bronchial epithelium. D shows, in
the same tissue sections as C, the selection of positive brown diaminobenzidine staining by the computer-aided system and
visualizes it as a red colour. E corresponds to IL-8 staining and F as a negative control.
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The cytokine expression in intact areas of the bronchial
epithelium was quantified using the computer-assisted
image analyser. The cytokine expression was given as the
percentage of positively immunostained epithelial area out
of the total epithelial area.11,12
Adhesion molecules
Quantification of endothelial adhesion molecule expression
was done by expressing the number of blood vessels stainedwith a specific anti-adhesion molecule mAb, as a percentage
of the total vessel complement, revealed by staining with
the pan-endothelial mAb EN4.13
Mitogen activated protein kinases and transcription
factors
Quantification of the immunoreactivity of phosphorylated
mitogen activated protein kinases (MAPkinases) and
transcription factors in the bronchial epithelium were
performed with the computer-assisted image analyser. The
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percentage of positively immunostained epithelial area out
of total epithelial area. The quantification of positively
stained cell nuclei or nuclear membranes was performed
using a light microscope. The result was referred to as
nuclear staining and expressed as the number of positive
nuclei/mm2 of bronchial epithelium.10,12
Statistical analysis
Statistical analysis was carried out with SPSS version 11.0
on a Windows based PC platform (SPSS, Inc., Chicago, IL,
USA). To analyse the differences between groups, the
ManneWhitney non-parametric U-test for two independent
samples was used. P-values from two-sided tests were
considered significant if less than 0.05. Correlations were
analysed using the non-parametric Spearman test where
P-values less than 0.05 were considered as significant.
Logistic regression analyses were carried out to investigate
whether a number of defined covariates could be predictors
of ILD in patient with SSc, or could predict SSc.
Results
Inflammatory state in the bronchial mucosa evaluated in all
SSc patients (nZ 23) in comparison with the healthy
controls.
The SSc patients demonstrated significantly higher
neutrophil numbers in the submucosa as compared with
healthy aged-matched controls (PZ 0.002). The number of
other inflammatory cells did not differ significantly. The
total epithelial expression and nuclear translocation of
NFkB were significantly decreased in SSc patients
(PZ 0.012 and 0.006, respectively), with similarly reduc-
tion in the expression of IL-8 (PZ 0.031) (which can be
controlled by NFkB and p-38 MAPkinase). A downward
trend, though non-significant, was seen for several of theTable 3 Comparison of cytokine expression in the bronchial epit
and endothelial adhesion molecules between SSc patients and ag
Controls NZ 17 SSc patients NZ 23
Neutrophilsb 35.3 (18.3e49.7) 73.4 (42.1e103)
Mast cellsb 25.8 (15.2e35.6) 29.1 (21.3e56.5)
CD3b 16.9 (5.65e42.6) 20.8 (8.90e30.4)
CD4b 2.8 (0.95e11.4) 2.10 (0.00e8.50)
CD8b 11.0 (5.90e26.9) 9.70 (3.60e24.3)
P-selectin %c 16.7 (3.75e34.3) 19.5 (7.10e29.7)
ICAM-1%c 32.7 (21.1e47.2) 30.0 (8.30e51.7)
IL-8d 1.0 (0.30e1.48) 0.40 (0.09e0.78)
Gro-ad 0.02 (0.00e0.12) 0.02 (0.00e0.09)
ENA-78d 0.24 (0.08e0.79) 0.17 (0.07e0.38)
Data are given as medians with 25the75th percentiles.
a P: refers to comparison with healthy controls.
b Positively stained cells/mm2 submucosa.
c % positive stained vessels compared with EN4 staining.
d % of epithelial surface with positive staining.MAPkinases. Other parameters did not differ between
groups (Tables 3 and 4).
When differences in airway mucosal inflammation were
identified between the total group of SSc patients and
controls, the second hypothesis was addressed, concerning
whether the group with SSc and interstitial lung disease
would have a more pronounced bronchial inflammation,
compared to SSc without ILD.
None of the investigated inflammatory markers were
related to the presence ILD, even when analysed with
adjustments for smoking, corticosteroid treatment and
secondary Sjogren’s syndrome (data not shown).
Since smoking as well as oral steroid treatment were
common in the SSc patients and are well known to influence
immunological events in the lungs, we further explored if
these factors could have influenced the outcomes.
When the four smokers and seven patients with oral
corticosteroid treatment were excluded from the analyses,
a total of 12 patients with SSc remained (Tables 3 and 4).
When comparing the investigated bronchial mucosal
parameters between these 12 SSc patients with the control
subjects, the SSc patients still had significantly higher
neutrophil numbers in the submucosa and lower epithelial
IL-8 and NFkB expression (in similarity with the total group
of 23 SSc patients). Neither smoking nor corticosteroid
therapy predicted the presence of ILD, analysed in logistic
regression analyses.
Discussion
The present study demonstrates that patients with SSc
show airway inflammation with accumulation of neutrophils
in the bronchial mucosa, as compared with a group of age
and sex-matched control subjects. The bronchial neutro-
philia was, however, not associated with any up-regulation
of neutrophil chemoattractants or other cytokines in the
bronchial epithelium. Conversely, the signal transductionhelium, inflammatory cells in the epithelium and submucosa,
e- and sex-matched healthy controls.
Pa SSc patients
(smokers and corticosteroid
treated patients excluded) NZ 12
Pa
0.002 74.5 (27.9e102) 0.042
0.10 36.8 (17.7e56.4) 0.16
0.71 28.0 (20.5e42.3) 0.29
0.31 5.65 (0.00e12.9) 0.69
0.73 18.0 (8.88e31.1) 0.36
0.73 25.0 (7.83e39.5) 0.48
0.52 38.0 (17.2e69.2) 0.64
0.031 0.33 (0.08e0.69) 0.035
0.95 0.01 (0.00e0.06) 0.64
0.39 0.15 (0.03e0.30) 0.16
Table 4 Comparison of intracellular signalling molecules in the bronchial epithelium, between SSc patients and age- and sex-
matched healthy controls.
Controls NZ 17 SSc patients NZ 23 Pa SSc patients (smokers
and corticosteroid treated
patients excluded) NZ 12
Pa
ERK tot b 0.50 (0.12e1.00) 0.13 (0.03e0.71) 0.08 0.09 (0.03e0.83) 0.11
ERK nuclc 1338 (589e2301) 705 (165e2052) 0.09 506 (135e1846) 0.13
JNK totb 0.40 (0.16e0.55) 0.14 (0.09e0.34) 0.08 0.14 (0.10e0.58) 0.20
JNK nuclc 1053 (548e1262) 564 (346e981) 0.06 545 (348e1026) 0.14
p38 totb 0.04 (0.01e0.11) 0.02 (0.00e0.14) 0.60 0.01 (0.00e0.04) 0.22
p38 nuclc 161 (63.6e681) 143 (26.4e799) 0.73 91.6 (29.8e218) 0.27
NFkB totb 0.06 (0.02e0.31) 0.02 (0.01e0.05) 0.012 0.02 (0.00e0.06) 0.017
NFkB nuclc 440 (156e1235) 169 (47.1e413) 0.006 72.9 (3.66e415) 0.006
c-Fos totb 0.05 (0.02e0.07) 0.02 (0.01e0.07) 0.21 0.02 (0.01e0.07) 0.23
c-Fos nuclc 309 (132e499) 147 (56.0e340) 0.11 85.2 (36.3e330) 0.08
c-Jun totb 0.64 (0.39e1.18) 0.59 (0.20e1.42) 0.65 0.37 (0.16e0.70) 0.07
c-Jun nuclc 1516 (1087e2176) 1434 (631e2136) 0.54 1191 (521e1553) 0.08
Data are given as Medians with 25the75th percentiles.
a P: refers to comparison with healthy controls.
b Positive cytoplasm and nuclei staining/mm2 epithelium.
c Numbers of nuclei/mm2 epithelium.
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kines, were either down-regulated or unchanged in the
epithelium. The effects observed in the bronchial mucosa
were present regardless of the presence of interstitial lung
disease (ILD), or whether patients were smoking or treated
with oral corticosteroids.
To our knowledge, inflammatory cell infiltration in the
airways of SSc patients has not previously been reported.
The present study demonstrates a pronounced increase in
neutrophils in the submucosa of SSc patients, compared
with healthy controls. Neutrophils are important cells in
the immune defence and may through oxidative burst and
secretion of oxidant enzymes induce cytotoxic effects as
well as damage to surrounding cells and structures during
inflammation.14e16 Neutrophils have been implied to play
a role in many bronchial conditions such as asthma, chronic
bronchitis and COPD.17,18
Cell recruitment into the airways is depending on several
factors, including signal transduction, cytokine release and
adhesion molecule expression. All these aspects were
addressed in the present biopsy material. We, as well as
others, have previously established the regulatory roles of
these events in respiratory diseases and airway responses to
environmental factors.10,19e21 NFkB and AP-1 are oxidative
stress-sensitive transcription factors that, following nuclear
translocation, regulate transcription of many important
inflammatory mediators and components, including cyto-
kines and adhesion molecules. NFkB in the bronchial
epithelium can also be regulated via cytokine receptors as
well as epidermal growth factor receptor (EGFR) and
phosphorylation of tyrosine kinases in the MAPkinase
family.10 The JNK MAPkinase pathway may also regulate AP-
1. The neutrophilic infiltration demonstrated could have
been initiated by the mentioned upstream signalling path-
ways via IL-8, GRO-a and up-regulation of the vascular
adhesion molecule expression of ICAM-1, which enables cell
migration from the blood circulation into the bronchialmucosa.22 In most states of acute bronchial inflammation,
the mentioned signal transduction pathways and proin-
flammatory components are up-regulated. Interestingly,
this was not the case for the neutrophilic bronchial
inflammation in SSc, where these components generally
were down-regulated or unchanged, in comparison with
healthy control subjects.
A major question, when the present findings were
considered, was whether the inflammatory changes in the
bronchial mucosa would be associated with the presence of
interstitial lung disease. In the present material 12 patients
had presence of ILD on HRCT and this group demonstrated
reduced TLC compared to those without ILD. A limitation in
the study was that in the investigated clinical material only
three SSc patients had extensive ILD. This is a common
occurrence of the severe ILD form in SSc. When comparing
SSc patients, with and without ILD, both groups demon-
strated similar changes in the bronchial mucosa. While
these groups were not extensive in numbers, being 11 and
12 subjects respectively, there was no tendency in the
distribution of the data or P-values suggesting that a type II
error should have masked a real difference between the
groups. A logistic regression analysis including smoking,
steroid treatment and presence of ILD pointed in the same
direction. We therefore have assumed the bronchial find-
ings of the study to be an inherent part of SSc, rather than
associated with the peripheral lung engagement in SSc with
ILD.
Since a number of the SSc patients were treated with
oral corticosteroids or were smokers, it was explored to
what extent this may have influenced the differences in the
investigated parameters, in relationship to the non-smoking
control group. With the smokers and oral steroid treated
patients excluded, 12 SSc patients remained. Despite the
fact that the number of subjects now was reduced by half,
the differences in bronchial inflammatory markers, were
still significant compared to controls. When exploring the
Airway inflammation in systemic sclerosis 307influence of oral corticosteroid treatment, it did, if
anything, tend to normalise the expression of transcription
factors and kinases. This further strengthens the impression
that SSc itself is associated with a neutrophilic inflamma-
tion in the bronchial mucosa, along with signs of suppres-
sion of signal transduction and cytokine expression in the
bronchial epithelium. The underlying mechanisms for the
suppression of signal transduction pathways remain to be
elucidated.
When it comes to the decrease in total and nuclear
staining for NFkB, the monoclonal antibody employed in
this study is directed at a site with transcription properties
on the p65 subunit. This site is concealed when NFkB is in
inactive form, as the inhibitory-kB (IkB) is bound to the
p65ep50 heterodimer at the corresponding position.23,24
The enzyme IkB kinase b (IKKb) is responsible for the
phosphorylation of IkB, resulting in the activation and
translocation of the p65ep50 complex into the nucleus,
where it can bind to promoter regions on DNA and facilitate
transcription. Since the antibody used for NFkB immu-
noactivity in the present study only identifies the active
form of p65, the findings indicate that the inflammatory
state in the airway in SSc may have affected IkB or IKK, thus
influencing the regulation of NFkB. Several cytoplasmic and
nuclear mechanisms have been shown to modulate the
binding and activity of NFkB.25,26 We have recently also
demonstrated a neutrophilic inflammation in the airspaces
in SSc, as reflected in bronchoalveolar lavage fluid, with
increased release of oxidative enzymes such as myeloper-
oxidase.5 Oxidative stress and reactive oxygen species26 are
normally able to activate NFkB in the cytoplasm through
the phosphorylation of IkB. However, it has been shown
that ROS may exert contrasting effects in the nucleus,
whereby oxidised NFkB may be inactivated and display
weaker DNA binding. This can be counteracted by reducing
enzymes such as thioredoxin (TRX) or redox factor 1.26
Oxidative stress in the airways could also potentially have
played a role for the observed bronchial mucosal neutro-
philia. In the absence of an increase in the neutrophil
chemoattractants IL-8, Gro-a and ENA-78 in the bronchial
epithelium, leukotriene-B4 is an interesting candidate for
neutrophil chemotaxis. Oxidation of lipids in the epithelial
lining fluid has been shown to activate phospholipase A2
(PLA2) and 5-lipooxygenase (5-LO), which lead to the
production of leukotrienes like LTB4.27 The processing of
biopsies in acetone in the present study prevented any
attempts to address LTB4 levels in the bronchial biopsies.
Another explanation for the increased number of neutro-
phils in the bronchial submucosa in SSc may be that
neutrophils are recruited due to a primary lesion of the
submucosal vessels, leading to the adhesion of neutrophils
to other endothelial adhesion molecules than ICAM-1 and
P-selectin, like E-selectin.28,29
It is concluded from the presently investigated clinical
material that regardless of the presence of interstitial lung
disease, SSc is associated with a chronic neutrophilic
inflammation and signs of suppressed signal transduction in
the bronchial mucosa. These findings contrast to the
neutrophil activation shown in the peripheral airspaces,
which has recently been implied to be involved in the
development of ILD, through modulation of the MMP-9 and
TIMP balance.5Conflict of interest
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